Phase 2 Study of Lenadogene Nolparvovec Gene Therapy for Leber Hereditary Optic Neuropathy: The REVISE Trial Isabella Ciccone, MPH

Published Date: 31 Jan 2026

The REVISE trial, a phase 2 study evaluating GenSight Biologics’ lenadogene nolparvovec in patients with Leber hereditary optic neuropathy, is expected to begin in January 2026.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Radioactive ion beams successfully treat animal tumors in study

2.

A computer-aided diagnostic system for improved detection of breast cancer.

3.

Ultrasound bras; HPV and thyroid cancer; language minimizing adverse events.

4.

Study reveals that older women frequently receive an incorrect breast cancer diagnosis.

5.

Durvalumab Plus BCG Earns FDA Nod for Bladder Cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot